Trial · NCT03269994
Does Cefoxitin or Piperacillin-Tazobactam Prevent Postoperative Surgical Site Infections After Pancreatoduodenectomy?
NCT03269994, Phase 3, Completed, Memorial Sloan Kettering Cancer Center; results first posted 2025-10-21
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Does Cefoxitin or Piperacillin-Tazobactam Prevent Postoperative Surgical Site Infections After Pancreatoduodenectomy? Trials, record NCT03269994. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03269994
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Does Cefoxitin or Piperacillin-Tazobactam Prevent Postoperative Surgical Site Infections After Pancreatoduodenectomy?
- NCT number
- NCT03269994
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 967 participants, actual
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Conditions
- Pancreatic Cancer, Pancreas Cancer, Pancreatic Diseases
- Interventions
- Cefoxitin, Piperacillin-tazobactam
- First posted
- 2017-09-01
- Last updated
- 2025-10-21
- Results first posted
- 2025-10-21
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants Evaluated for the Effectiveness of Cefoxitin as a Surgical Antibiotic Prophylaxis. | 30 days | To compare the effectiveness of cefoxitin, a second generation cephalosporin (Cohort 1), with piperacillin-tazobactam, a broad-spectrum penicillin (Cohort 2), as surgical antibiotic prophylaxis in decreasing the overall rate of postoperative SSIs in patients undergoing PD. The primary endpoint, overall SSI rate, is defined as superficial incisional SSI, deep incisional SSI, or organ/space SSI within the first 30 days after the operation, as defined according to the ACS NSQIP data collection operations manual. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants Evaluated for the Effectiveness of Cefoxitin as a Surgical Antibiotic Prophylaxis. | 30 days | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants Evaluated for the Effectiveness of Cefoxitin as a Surgical Antibiotic Prophylaxis. | Cefoxitin | 400 | Participants | ||
| Number of Participants Evaluated for the Effectiveness of Cefoxitin as a Surgical Antibiotic Prophylaxis. | Piperacillin-tazobactam | 378 | Participants |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Cefoxitin | 484 | |
| Overall Study | STARTED | Piperacillin-tazobactam | 483 | |
| Overall Study | COMPLETED | Cefoxitin | 400 | |
| Overall Study | COMPLETED | Piperacillin-tazobactam | 378 | |
| Overall Study | NOT COMPLETED | Cefoxitin | 84 | |
| Overall Study | NOT COMPLETED | Piperacillin-tazobactam | 105 |
Source ClinicalTrials.gov
Adverse events2
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| serious | Death | General disorders | Cefoxitin | 10 | 400 | |
| serious | Death | General disorders | Piperacillin-tazobactam | 5 | 378 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Cefoxitin | 10 | 400 |
| Total, all-cause mortality | Piperacillin-tazobactam | 5 | 378 |
| Total, other adverse events | Cefoxitin | 0 | 400 |
| Total, other adverse events | Piperacillin-tazobactam | 0 | 378 |
| Total, serious adverse events | Cefoxitin | 10 | 400 |
| Total, serious adverse events | Piperacillin-tazobactam | 5 | 378 |
Source ClinicalTrials.gov
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons3
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Cefoxitin vs Piperacillin-tazobactam: Number of Participants Evaluated for the Effectiveness of Cefoxitin as a Surgical Antibiotic Prophylaxis. | Trial comparisons |
| Cefoxitin vs Piperacillin-tazobactam: deaths from any cause | Trial comparisons |
| Cefoxitin vs Piperacillin-tazobactam: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03269994
GET https://conductscience.org/api/trials/v1/NCT03269994/registered